BRIEF—Teva launches US generic of big-selling OAB drug

Israeli drugmaker Teva Pharmaceutical Industries has launched a generic version of the overactive bladder (OAB) drug VESIcare (solifenacin succinate) in the USA.

Teva will sell 5mg and 10mg tablet versions of the Astellas drug, which has annual sales of more than $955 million in the USA alone, according to IQVIA data as of February 2019.

OAB affects around 33 million Americans and the condition is most often characterized by a strong sudden urge to urinate that is difficult to control.